Read on Twitter
$KALV the bigger thesis for what is only a $650M EV at pre market levels-
Readthru to Prophylactic is the endgame. Ability to demo CLEAN efficacy AND safety w/ acute suggests have chemistry/PK/PD nailed down- BIG
Acquisitive space w/ Shire/Tak
Comps valued higher(see $PHVS) https://twitter.com/bio_clouseau/status/1359144133798076417
Readthru to Prophylactic is the endgame. Ability to demo CLEAN efficacy AND safety w/ acute suggests have chemistry/PK/PD nailed down- BIG
Acquisitive space w/ Shire/Tak
Comps valued higher(see $PHVS) https://twitter.com/bio_clouseau/status/1359144133798076417
The attempt to comp $KALV data to $BCRX to try and nitpick is absurd. There’s a reason why BCRX no longer pursuing acute
BCRX acute data were well below par, and the trial was essentially unblinded, both by its design as well as the foul smell/taste of the slurry solution
BCRX acute data were well below par, and the trial was essentially unblinded, both by its design as well as the foul smell/taste of the slurry solution
(That in itself makes it unviable- imagine trying to scramble together an unpleasant concoction while your attack ramps)
BCRX despite very iffy PK/PD and multiple fails was valued $1-1.5B+, even in markets less frothy than today’s (~double $KALV current EV)
BCRX despite very iffy PK/PD and multiple fails was valued $1-1.5B+, even in markets less frothy than today’s (~double $KALV current EV)
